Srikripa Devarakonda
Stock Analyst at Truist Securities
(0)
# 3182
Out of 5,240 analysts
59
Total ratings
32.56%
Success rate
3.98%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Regeneron Pharmaceut... | Maintains: Buy | 1126 1004 | 690.23 | 45.46% | 5 | Jan 8, 2025 | |
Biogen | Maintains: Buy | 302 220 | 143 | 53.85% | 2 | Jan 8, 2025 | |
AbbVie | Maintains: Buy | 215 211 | 175.46 | 20.26% | 2 | Jan 8, 2025 | |
Keros Therapeutics | Maintains: Buy | 100 43 | 12.52 | 243.45% | 4 | Dec 23, 2024 | |
Pfizer | Maintains: Buy | 36 32 | 26.41 | 21.17% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 33 50 | 27.55 | 81.49% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 36 45 | 41.52 | 8.38% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 54 53 | 40.09 | 32.2% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 1000 1033 | 743.02 | 39.03% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 54 54 | 4.16 | 1198.08% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 83 74 | 71.9 | 2.92% | 8 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | 36.62 | 63.84% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 15 | 5.05 | 197.03% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 36 | 18.56 | 93.97% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 86 70 | 45.16 | 55% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 60 | 1.05 | 5614.29% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 38 | n/a | n/a | 3 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 50 34 | n/a | n/a | 2 | Jun 3, 2021 |